Zinc protoporphyrin IX (ZnPP) is a member of metalloporphyrins in which the heme iron is replaced by zinc, which becomes a competitive inhibitor of heme oxygenase 1 (HO-1) [1].
Zinc protoporphyrin IX tested presented anti-vesicular stomatitis virus (VSV) activity without photoactivation, with the reduction in viral titer being about 10-fold for 1 μM Zinc protoporphyrin. At 5 μM, Zinc protoporphyrin IX tested were able to completely abolish VSV infectivity. Photoactivation of the porphyrins significantly enhanced their antiviral activities, with 0.1 μM ZnPPIX completely abolishing VSV infectivity [2]. Zinc protoporphyrin IX (ZnPP) (5 μM; 72 hours) causes the fraction of late apoptotic and necrotic cells increasing from 10.9% in controls to 30.4% after 72 h in C-26 cells[3]. Zinc protoporphyrin IX (1.25-40 μM; 48 or 72 hours) exerts cystostatic/cytotoxic effects against human ovarian carcinoma (MDAH2774), human pancreatic adenocarcinoma (Mia PaCa2), human breast carcinoma (MDA-MB231), murine breast carcinoma (EMT6) cell lines [3].
Zinc Protoporphyrin IX (12.5, 25, 50 mg/kg for i.p.; 12.5, 50 mg/kg for p.o. for 7days) exerts dose-dependent antitumor effects manifested by the retardation of tumor growth in BALB/c mice inoculated with C-26 cells [3]. Zinc Protoporphyrin IX (5 and 20 μg/mouse) dose-dependently inhibited tumor growth in LL/2-tumor model mice. Vascular endothealial growth factor concentration in tumors was reduced by Zinc Protoporphyrin IX [4].
References:
[1]. Fang J, Greish K, Qin H, et al. HSP32 (HO-1) inhibitor, copoly (styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: In vitro and in vivo anticancer effect[J]. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81(3): 540-547.
[2]. Cruz-Oliveira C, Almeida A F, Freire J M, et al. Mechanisms of vesicular stomatitis virus inactivation by protoporphyrin IX, zinc-protoporphyrin IX, and mesoporphyrin IX[J]. Antimicrobial agents and chemotherapy, 2017, 61(6): e00053-17.
[3]. Nowis D, Bugajski M, Winiarska M, et al. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice[J]. BMC cancer, 2008, 8(1): 1-12.
[4]. Hirai K, Sasahira T, Ohmori H, et al. Inhibition of heme oxygenase‐1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice[J]. International Journal of Cancer, 2007, 120(3): 500-505.
锌原卟啉 IX (ZnPP) 是金属卟啉中的一员,其中血红素铁被锌取代,成为血红素加氧酶 1 (HO-1) 的竞争性抑制剂[1]。\n
经过测试的锌原卟啉 IX 具有抗水疱性口炎病毒 (VSV) 活性,无需光活化,对于 1 μM 原卟啉锌,病毒滴度降低约 10 倍。在 5 μM 时,经过测试的锌原卟啉 IX 能够完全消除 VSV 感染性。卟啉的光活化显着增强了它们的抗病毒活性,0.1 μM ZnPPIX 完全消除了 VSV 感染性[2]。锌原卟啉 IX (ZnPP)(5 μM;72 小时)导致晚期凋亡和坏死细胞的比例从对照中的 10.9% 增加到 72 小时后 C-26 细胞中的 30.4%[3]。锌原卟啉 IX(1.25-40 μM;48 或 72 小时)对人卵巢癌 (MDAH2774)、人胰腺癌 (Mia PaCa2)、人乳腺癌 (MDA-MB231)、鼠类乳腺癌 (EMT6) 具有抑囊/细胞毒性作用细胞系[3].
锌原卟啉 IX(腹腔注射 12.5、25、50 mg/kg;口服 12.5、50 mg/kg,持续 7 天)在接种 C 的 BALB/c 小鼠中发挥剂量依赖性抗肿瘤作用,表现为肿瘤生长迟缓-26 个细胞 [3]。锌原卟啉 IX(5 和 20 μg/小鼠)剂量依赖性地抑制 LL/2 肿瘤模型小鼠的肿瘤生长。 Zinc Protoporphyrin IX降低了肿瘤中血管内皮生长因子的浓度[4]。
经过测试的锌原卟啉 IX 具有抗水疱性口炎病毒 (VSV) 活性,无需光活化,对于 1 μM 原卟啉锌,病毒滴度降低约 10 倍。在 5 μM 时,经过测试的锌原卟啉 IX 能够完全消除 VSV 感染性。卟啉的光活化显着增强了它们的抗病毒活性,0.1 μM ZnPPIX 完全消除了 VSV 感染性[2]。锌原卟啉 IX (ZnPP)(5 μM;72 小时)导致晚期凋亡和坏死细胞的比例从对照中的 10.9% 增加到 72 小时后 C-26 细胞中的 30.4%[3]。锌原卟啉 IX(1.25-40 μM;48 或 72 小时)对人卵巢癌 (MDAH2774)、人胰腺癌 (Mia PaCa2)、人乳腺癌 (MDA-MB231)、鼠类乳腺癌 (EMT6) 具有抑囊/细胞毒性作用细胞系[3].
锌原卟啉 IX(腹腔注射 12.5、25、50 mg/kg;口服 12.5、50 mg/kg,持续 7 天)在接种 C 的 BALB/c 小鼠中发挥剂量依赖性抗肿瘤作用,表现为肿瘤生长迟缓-26 个细胞 [3]。锌原卟啉 IX(5 和 20 μg/小鼠)剂量依赖性地抑制 LL/2 肿瘤模型小鼠的肿瘤生长。 Zinc Protoporphyrin IX降低了肿瘤中血管内皮生长因子的浓度[4]。
















